TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00703976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
Study: NCT04760587

Intervention type: BEHAVIORAL
Intervention: smart devices in adolescent weight control
Description: The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
Study: NCT05783856

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo X-secret
Description: In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
Study: NCT00193973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
Description: Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
Study: NCT02434263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydra TAVI
Description: Percutaneous Replacement of the Diseased Aortic Valve
Study: NCT03847194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
Study: NCT02720133

Intervention type: BIOLOGICAL
Intervention: biochemical parameters
Description: patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison.
Study: NCT03064243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 500mg po. qd.
Study: NCT01391845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 30mg of ulipristal acetate orally the day of hCG injection in a unique dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally in a unique dose the day of hCG injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: ulipristal acetate 30mg orally in a unique dose the day of hCG administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally in a unique dose the day of hCG injection
Study: NCT03766139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUPERCELL GLUE
Description: Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRFM ALONE
Description: Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
Study: NCT01032460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the macintosh laryngoscope
Description: intubate with the macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the C-MAC laryngoscope
Description: intubate with the C-MAC laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubate with the Airtraq device
Description: intubate with the Airtraq device
Study: NCT01921231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Prilocaine 1%
Description: Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5%
Description: Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
Study: NCT02215668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Exercise muscle stretching and body warming.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Exercise muscle stretching and body warming.
Study: NCT02203617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Content/Pediatric Anticipatory Guidance
Description: educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
Study: NCT02573168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
Study: NCT02040948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: - Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)
Study: NCT01115569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
Study: NCT03132792

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified AFPᶜ³³²T cells
Description: Infusion of autologous genetically modified AFPᶜ³³²T cells
Study: NCT01831973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Study: NCT03023644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Description: Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
Study: NCT01507610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
Study: NCT02391246

Intervention type: OTHER
Intervention: Positron Emission Tomography Imaging
Description: Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
Study: NCT02203617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book provision
Description: Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book provision
Description: Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
Study: NCT02176668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 100
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 100
Description: The number of times : multiple-dose Rout : oral administration
Study: NCT01286415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Present Centered Therapy
Description: Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
Study: NCT04036162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: MagnetoEncephaloGraphy (MEG) records

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: MagnetoEncephaloGraphy (MEG) records
Study: NCT00569946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT03893591

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Xa levels
Description: one Blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Xa levels
Description: one Blood sample
Study: NCT00762463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: capsule, 200 mg QD, 6-12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac SR
Description: tablet, 75 mg QD,6-12 weeks
Study: NCT04473950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone Hydrochloride
Description: An intramuscular (IM) injection of naloxone will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Hydrochloride
Description: An intramuscular (IM) injection of naloxone will be given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An IM injection of 0.9% normal saline will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An IM injection of 0.9% normal saline will be given.
Study: NCT04442984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: d1 Irinotecan 180mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study: NCT01507610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
Study: NCT01032512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SUPPORTAN + GLUTAMINE PLUS
Description: 600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: NO PREOPERATIVE NUTRITION SUPPORT
Description: Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
Study: NCT02689336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT03229759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidine Dihydrocloride in aqueous solution
Description: application of investigational product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: application of vehicle control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control
Description: application of placebo
Study: NCT01146067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Rivastigmine capsules 1.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine capsules 1.5 mg
Study: NCT02176668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 OF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 200
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 400
Description: The number of times : multiple-dose Rout : oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 NF 400
Description: The number of times : multiple-dose Rout : oral administration
Study: NCT01454440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Study: NCT01402765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit first
Description: Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nimbus 3 first
Description: Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
Study: NCT01717911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
Study: NCT02980783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT®™ with Lidocaine
Description: Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
Study: NCT01454440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eptifibatide
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Study: NCT02882269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
Study: NCT02013531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
Study: NCT01314768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention
Description: Structured behavioural Brief intervention given by trained GPs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Business as usual
Description: GPs to treat patient as they have until now based on best established practice

Intervention type: OTHER
Group type: OTHER
Intervention: Screening and outcome evaluation only
Description: No additional intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Screening and outcome evaluation only
Description: No additional intervention
Study: NCT00774943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 557
Description: A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
Study: NCT00880542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
Study: NCT00910026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low tidal volume ventilation
Description: 6 ml/kg tidal volume ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high tidal volume ventilation
Description: 12 ml/kg tidal volume ventilation